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Abstract
Background: A novel member of the Wnt signalling pathway, Chibby, was recently identified. This
protein inhibits Wnt/β-catenin mediated transcriptional activation by competing with Lef-1 (the
transcription factor and target of β-catenin) to bind to β-catenin. This suggests that Chibby could
be a tumour suppressor protein. The C22orf2 gene coding Chibby is located on chromosome 22,
a region recurrently lost in colorectal cancer. Activation of the Wnt pathway is a major feature of
colorectal cancer and occurs through inactivation of APC or activation of β-catenin. All of this led
us to analyse the possible implication of Chibby in colorectal carcinogenesis.
Methods: First, 36 tumour and matched normal colonic mucosa DNA were genotyped with five
microsatellite markers located on chromosome 22 to search for loss of heterozygosity. Then,
mutation screening of the C22orf2 coding sequence and splice sites was performed in the 36
tumour DNA. Finally, expression of Chibby was analysed by quantitative RT-PCR on 10 patients,
4 with loss of heterozygosity (LOH) on chromosome 22.
Results: Loss of heterozygosity involving the C22orf2 region was detected in 11 out of 36 patients
(30%). Sequencing analysis revealed a known variant, rs3747174, in exon 5: T321C leading to a
silent amino acid polymorphism A107A. Allelic frequencies were 0.69 and 0.31 for T and C variants
respectively. No other mutation was detected. Among the 10 patients studied, expression analysis
revealed that Chibby is overexpressed in 2 tumours and underexpressed in 1. No correlations
were found with 22q LOH status.
Conclusion: As no somatic mutation was detected in C22orf2 in 36 colorectal tumour DNA, our
results do not support the implication of Chibby as a tumour suppressor in colorectal
carcinogenesis. This was supported by the absence of underexpression of Chibby among the
tumour samples with 22q LOH. The implication of other Wnt pathway members remains to be
identified to explain the part of colorectal tumours without mutation in APC and β-catenin.
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Background
Identifying components of the Wnt signalling pathway
has been at the forefront of cancer biology since a link was
made between Wnt, the mammalian homologue of the
fruitfly Wingless (Wg), and the development of cancer.
Acting through a core set of proteins that are highly con-
served in evolution, this pathway regulates the ability of
the oncoprotein β-catenin to activate transcription of spe-
cific target genes. This regulation, in turn, results in
changes in expression of genes that modulate cell fate,
proliferation and apoptosis [1]. Recently, Takemaru et al.
identified a novel human protein, named Chibby, that
interacts with the carboxy-terminal transcription activa-
tion domain of β-catenin [2]. Chibby is a nuclear protein
of 126 amino acids with coiled-coil domains and is con-
served from Drosophila to Human. It has been shown
that Chibby antagonizes the Wnt signalling pathway by
inhibition of the transcription protein complex compris-
ing β-catenin. This result suggests that Chibby could act as
a tumour suppressor protein.
In colorectal cancer, the activation of the Wnt signalling
pathway occurs in more than 60% of tumours through the
inactivation of the APC tumour suppressor gene by muta-
tions and allelic losses, or through the presence of β-cat-
enin activating mutations [3]. The C22orf2 gene encoding
Chibby is located on 22q13.1. This chromosome region is
frequently lost in colorectal cancer suggesting the exist-
ence of a tumour suppressor gene that remains to be
identified.
The putative function and the location of the C22orf2 gene
led us to analyse the possible implication of C22orf2 as a
tumour suppressor gene in colorectal carcinogenesis.
First, the allelic status of chromosome 22 was established
on 36 colorectal tumour and matched normal colonic
mucosa DNA, second, mutation analysis of the C22orf2
gene was performed on tumour DNA, and third, expres-
sion analysis of Chibby was studied in few patients.
Methods
Patients, sample collection and nucleic acid extraction
Tumour samples and matched normal colonic mucosa
were collected from 36 patients (23 women, 13 men) hos-
pitalised in the surgical department of Laennec Hospital
in Paris between 1997 and 1999. The mean age of patients
was 69.9 years old, range [56.4–83.4]. An histological
HES staining was performed before DNA extraction and
only tumour fragments with more than 70% of tumour
cells were retained. Tumours were all classified as adeno-
carcinoma. Twenty-nine tumours were classified as well
differentiated, and 7 as poor differentiated. No tumour
samples showed a microsatellite instability phenotype.
Tumours were located in proximal colon in 9 cases, in dis-
tal colon in 21 cases and 6 were located in rectum. Accord-
ing to TNM classification, tumours were classified in stage
I in 1 case, stage II in 17, stage III in 8 and stage IV in 10
cases. Samples were immediately frozen in liquid nitrogen
and stored at -80°C. Informed consent was signed accord-
ing to French laws. DNA extraction was performed using
the QIAamp®  DNA Mini Kit (Qiagen, Courtaboeuf,
France) for all patients in 1999, and stored at -20°C.
Tumour samples and matched normal colonic mucosa
were available for RNA extraction for 10 patients. RNA
isolation was performed recently with RNeasy® Mini Kit
(Qiagen) and stored at -80°C. Quality of RNA was deter-
mined by electrophoresis through agarose gel stained with
ethidium bromide. Intensity of 18S and 28S RNA bands
was estimated under UV light. Measuring UV absorbance
at 260 nm was performed to quantify RNA.
Genotyping
Thirty-six tumour and matched normal colonic mucosa
DNA were genotyped with five microsatellite markers
located on chromosome 22. Amplification of the five
markers was performed by multiplex PCR using 50 ng
DNA in a final reaction volume of 12.5 µL using 6.25 µL
of 2X Qiagen Multiplex PCR Master Mix (Qiagen) and var-
iable concentration of primers as given in Table 1
(Goasguen  et al, unpublished data). Primers are from
Linkage Mapping Set (Applied Biosystems, Courtaboeuf,
France) and labelled on forward primer by VIC, NED or 6-
FAM. Amplified fragments were analysed after dilution on
an ABI 310 Genetic Analyzer (Applied Biosystems). Allelic
imbalance (AI) was analysed by Genotyper 2.1® software
(Applied Biosystems) with an automatic data-processing
trace program described previously [4]. AI was defined for
each tumor as α = (NL/NS)/(TL/TS) where L is the inten-
sity of the larger allele and S the intensity of the smaller
allele in normal DNA (N) or tumour DNA (T). When
α(loss of the small allele) or 1/α (loss of the large allele)
was ≤ 0.5, LOH was ascertained.
Sequencing analysis
PCR amplification of the four C22orf2 coding exons and
intron-exon junctions was performed as described in
Table 2. Due to the small size of intron 3, exons 3 and 4
were amplified together. 100 ng of tumour DNA were
used in a final reaction volume of 30 µL. For exons 2 and
3–4, 0.75 U of AmpliTaq® polymerase (Applied Biosys-
tems) were used with 3 µL of 10X corresponding buffer,
1.5 mM MgCl2, 800 µM of dNTP mix and 0.3 µM of each
forward and reverse primers. Program was as follows : ini-
tial step at 94°C 5 min, 35 cycles of 94°C 30 s, 58°C 30 s
and 72°C 30 s, and final step 72°C 7 min. For exon 5,
0.75 U of HotStarTaq® polymerase (Qiagen) were used
with the same protocol except the initial step at 95°C 10
min and the annealing temperature at 56°C. PCR prod-
ucts were purified by centrifugation on a Sephadex G-100®
(Amersham Biosciences, Orsay, France) filter loaded in aBMC Cancer 2004, 4:31 http://www.biomedcentral.com/1471-2407/4/31
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MultiScreen® plate (Millipore, Molsheim, France). Then
direct sequencing was performed in both forward and
reverse orientation from 2 µL of purified products using 2
µL of 2.5X BigDye™ Terminator v3.1 Ready Reaction Cycle
Kit (Applied Biosystems) with 3 µL of 5X corresponding
buffer and 0.5 µM of primer in a final reaction volume of
20 µL. Products were purified on Sephadex G-50® (Amer-
sham Biosciences) and analysed on an ABI 310 Genetic
Analyzer (Applied Biosystems). Sequence data were
aligned using AutoAssembler™ 2.0 software (Applied
Biosystems).
Quantitative RT-PCR
Three µg of RNA were reverse transcribed in a final volume
of 50 µL using the High Capacity cDNA Archive Kit with
random primers (Applied Biosystems). Reverse tran-
scribed samples were diluted 20 fold in water and stored
at -20°C. For each sample, 5 µL of cDNA, corresponding
to 15 ng of reverse transcribed RNA, were analysed by
SYBR Green PCR, in triplicate, using the ABI PRISM®
7900HT Sequence Detection System (Applied Biosys-
tems). Q-PCR was performed in a final volume of 12 µL
comprising 1X Master Mix SYBR Green (ABgene, Court-
aboeuf, France) and 0.3 µM of forward and reverse prim-
ers for Chibby (Fwd: 5'-GGAGAAAACCAAGATTCCAG-3'
; Rev: 5'-CCAACACAACCCAACAGAG-3'). Levels of RNA
expression were determined using the SDS software ver-
sion 2.1 (Applied Biosystems) according to the 2-∆∆Ct
method. Briefly, expression results of a gene were normal-
ised to internal control ribosomal 18S and relatively to a
calibrator, consisting in the mean expression level of the
corresponding gene in normal colonic mucosa samples as
follows : 2-∆∆Ct = 2-((Ct Chibby - Ct 18S)tumour sample) - (Ct Chibby - Ct
18S) calibrator)). Results are given in Table 3, they express the
n-fold ratio of the gene expression in a sample compared
to the mean of normal tissues. A ratio ≤ 0.66 has been
considered as underexpression of Chibby and ≥ 1.5 as
overexpression.
Results
Loss of heterozygosity analysis on chromosome 22
Five dinucleotide microsatellite markers spread over the
entire chromosome 22 were genotyped in order to deter-
mine the existence of a loss of heterozygosity (LOH). The
human gene coding Chibby, C22orf2, is localised between
the markers D22S283 and D22S423 (Table 1). Thirty-six
tumour and matched normal colonic mucosa DNA were
amplified by multiplex PCR. A deletion of the entire chro-
mosome 22 arm was observed in 9 cases, a distal deletion
including C22orf2 was observed in 2 cases (Figure 1) and
an interstitial deletion encompassing the D22S315 was
observed in one case. Thus, among the 36 tumours, 11
(30%) demonstrated LOH involving the C22orf2 region.
Sequencing analysis of C22orf2
The C22orf2 gene spreads over 17.2 kb and comprises five
exons. ORF starts at exon 2 leading to a 381 bp cDNA.
Coding sequence and intron exon junctions were ana-
lysed by direct sequencing on the 36 tumour DNA to
search for sequence variations. A known variant,
Table 1: Microsatellite markers analysed on chromosome 22
Markers 5'location on chromosome 22 (bp) label (on 
forward primer)
concentration for Multiplex PCR (µM) PCR product (bp)
D22S420 16133834 VIC 0,125 153–169
D22S315 24240393 6-FAM 0,5 180–210
D22S283 34922517 NED 0,125 127–155
C22orf2 37295719
D22S423 38525224 VIC 0,125 287–309
D22S274 43445681 NED 0,25 276–298
Table 2: PCR conditions for sequencing analysis of the C22orf2 gene
xon Primers (5'-3') Annealing temperature (°C) PCR product (bp)
2 ex2F: GGCATAAGGTCAGTGATCCAG 58 236
ex2R: TTCAGAGACACGCCTCAGCAC
3–4 ex3F: GGTCATATTGTTGGCGGAAG 58 490
ex4R: CCAAACTGGCATTGAGGAGA
5 ex5F: CCAGCAGCATCAGAGAAGTG 56 245
ex5R: AAAAGCACTCAGCCACATCCBMC Cancer 2004, 4:31 http://www.biomedcentral.com/1471-2407/4/31
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rs3747174, was observed in exon 5 leading to a T321C
transition, corresponding to a silent polymorphism
A107A. Allelic frequencies were 0.69 and 0.31 for T and C
variants respectively. The distribution of the different gen-
otypes is in agreement with Hardy and Weinberg equilib-
rium. No other somatic mutation was detected either in
coding exons or in splice sites.
Expression analysis of Chibby
The difference of the level of expression of Chibby
between tumour samples and normal colonic mucosa
samples was analysed by quantitative RT-PCR, using
ribosomal 18S as internal control. Both samples were
available for 10 patients, 4 of which presented LOH on
chromosome 22. Q-PCR expression analysis revealed that
Chibby is overexpressed in 2 tumours and underexpressed
in 1 (Table 3). No correlations were found with 22q LOH
status.
Discussion
The aim of this study was to analyse the possible implica-
tion of Chibby in colorectal carcinogenesis. Genotyping
analysis was performed on chromosome 22 to search for
loss of heterozygosity. Among the 36 patients, 12 (33%)
showed LOH including the C22orf2  region. Mutation
analysis was performed on C22orf2 coding sequence and
splice sites: no somatic mutation was detected. However,
a known variant, rs3747174, was observed in exon 5:
T321C, corresponding to A107A. In the dbSNP database
http://www.ncbi.nlm.nih.gov/SNP/, this variant was
detected with a set of 52 chromosomes and allelic fre-
quencies were estimated from 1496 chromosomes at 0.63
and 0.37 respectively which is similar to that observed in
this present series, i.e. 0.67 and 0.31 respectively [5]. Fur-
thermore, quantitative RT-PCR expression analysis
showed that Chibby is overexpressed in 2 tumours, 1 of
which showing LOH at C22orf2  locus, and Chibby is
underexpressed in 1 tumour showing no 22q LOH. Tak-
ing together, these results do not support a putative epige-
netic modification, i.e. methylation of the C22orf2
promoter, that could repress gene expression as another
mechanism of gene inactivation than mutation. Thus,
Chibby does not seem implicated as a tumour suppressor
in colorectal carcinogenesis.
Conclusions
The  APC  gene was found mutated in several series of
colorectal tumours with a frequency of 60%. Furthermore,
in a series of tumours lacking APC mutations, 48% pre-
sented a mutation in the β-catenin regulatory domain [3].
Thus, more than one gene could be implicated in
colorectal carcinogenesis through the activation of the
Wnt signalling pathway. The recently identified function
of Chibby in this pathway supports the idea that it could
act as a tumour suppressor [2]. However, we did not
detect mutation in a series of 36 colorectal tumours, sug-
gesting that the role of Chibby in colorectal carcinogenesis
is probably weak. Other genes remain to be studied to
explain the part of colorectal tumours without mutation
in APC and β-catenin.
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Table 3: Expression analysis of Chibby by Quantitative RT-PCR
Patient 2-∆∆Ct Expression of Chibby in tumour tissues compared to normal tissues LOH on chromosome 22
20 0.46 underexpressed no
27 0.78 similar no
33 1.23 similar no
26 1.43 similar no
2 1.48 similar no
19 1.57 overexpressed no
22 0.93 similar yes
24 1.24 similar yes
14 1.34 similar yes
3 2.26 overexpressed yesBMC Cancer 2004, 4:31 http://www.biomedcentral.com/1471-2407/4/31
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Microsatellite markers used for genotyping of chromosome 22 Figure 1
Microsatellite markers used for genotyping of chromosome 22. Genotyper® graphs obtained after multiplex PCR of 
the five microsatellite markers on chromosome 22 are shown on A, B, C, D, E. In each case the upper graph corresponds to 
the tumour DNA and the lower graph to the matched normal colonic mucosa DNA. Peaks are labelled with: name of markers, 
size of PCR products (bp) and peak intensity. A and B show no allelic loss for D22S420 and D22S315, whereas C, D and E 
show allelic loss for DS22S283, D22S423, D22S274. These results suggest a distal deletion of chromosome 22 including the 
C22orf2 gene.
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